Treatment strategy for EGFR mutated NSCLC
Mené sur 369 patients atteints d'un cancer du poumon non à petites cellules avec EGFR muté et de stade localement avancé ou métastatique, cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie sans progression, et la sécurité du rézivertinib et du géfinitib en traitement de première ligne
The treatment strategy based on recent progress in treatment in patients with non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations has certainly diversified. Treatment options include EGFR–tyrosine kinase inhibitors (TKIs), with or without additional treatment modalities such as chemotherapy or anti-vascular endothelial growth factor and its receptor antibody, in addition to other combinations with targeted drugs according to their diverse clinical characteristics or genetic alterations. EGFR TKIs are undoubtedly the backbone treatment for these patients, and osimertinib provides a good balance of efficacy and toxicity.1 Therefore, osimertinib has become the preferred treatment option over the past 5 years. This indicates that osimertinib is superior to f irst-generation EGFR TKIs in progression-free survival and is feasible in terms of adverse events.